Abivax S.A. SEC filings AAVXF

Abivax S.A. has 105 filings in SEC EDGAR's recent list, going back to Dec 16, 2022. Its latest annual report, Form 20-F, was filed on Mar 23, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Sep 21, 2026. The company's fiscal year ends on December 31.

Abivax S.A. SEC filings
Form Description Filed Period
POSASR Filing Jun 30, 2026 —
EFFECT Filing Nov 26, 2024 —
CORRESP Letter to the SEC Nov 25, 2024 —
UPLOAD Letter from the SEC Nov 22, 2024 —
SEC STAFF LETTER Filing Oct 20, 2023 —
EFFECT Filing Oct 19, 2023 —
EFFECT Filing Oct 19, 2023 —
CERT Filing Oct 19, 2023 —
8-A12B Filing Oct 18, 2023 —
CORRESP Letter to the SEC Oct 18, 2023 —
CORRESP Letter to the SEC Oct 18, 2023 —
CORRESP Letter to the SEC Oct 18, 2023 —
UPLOAD Letter from the SEC Oct 17, 2023 —
CORRESP Letter to the SEC Oct 16, 2023 —
UPLOAD Letter from the SEC Oct 5, 2023 —
CORRESP Letter to the SEC Sep 29, 2023 —
SEC STAFF LETTER Filing Sep 20, 2023 —
UPLOAD Letter from the SEC Sep 20, 2023 —
DRSLTR Filing Sep 8, 2023 —
DRS/A Filing Sep 8, 2023 —
UPLOAD Letter from the SEC Aug 18, 2023 —
DRSLTR Filing Jul 28, 2023 —
DRS/A Filing Jul 28, 2023 —
UPLOAD Letter from the SEC Jan 12, 2023 —
DRS Filing Dec 16, 2022 —

Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
ABVX (Nasdaq), AAVXF (OTC)
Fiscal year ends
December 31
Incorporated in
France
Headquarters
Paris
SEC filer status
Accelerated filer, Emerging growth company
SEC CIK
1956827

Other Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.